Cardiff Oncology, Inc.
CRDF
$1.05
-$0.05-4.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 25.22% | -71.08% | 35.90% | 19.26% | -3.79% |
| Total Depreciation and Amortization | 0.45% | -0.90% | -0.45% | -2.18% | 0.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.37% | 42.07% | -2.56% | -18.09% | 12.54% |
| Change in Net Operating Assets | -108.61% | -2,148.05% | 91.74% | -123.28% | 590.69% |
| Cash from Operations | 4.26% | -105.93% | 44.92% | -30.09% | 34.91% |
| Capital Expenditure | -- | -- | 100.00% | 30.77% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 278.05% | -69.70% | 5.61% | 305.33% | 66.01% |
| Cash from Investing | 276.70% | -69.70% | 5.80% | 303.89% | 65.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 102.86% | -95.89% | 10,112.00% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 41.90% | -95.89% | 10,112.00% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.32% | -221.69% | 1,230.20% | 95.12% | 51.38% |